{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T22:37:29Z","timestamp":1762036649454,"version":"build-2065373602"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00280-021-04258-6","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T08:03:04Z","timestamp":1616745784000},"page":"69-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Selinexor population pharmacokinetic and exposure\u2013response analyses to support dose optimization in patients with diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-8694","authenticated-orcid":false,"given":"Hongmei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russ","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin C.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"issue":"5","key":"4258_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","volume":"4","author":"DSP Tan","year":"2014","unstructured":"Tan DSP, Bedard PL, Kuruvilla J, Siu LL, Razak AR (2014) Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov 4(5):527\u2013537","journal-title":"Cancer Discov"},{"issue":"1","key":"4258_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","volume":"7","author":"GL Gravina","year":"2014","unstructured":"Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C (2014) Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol 7(1):85","journal-title":"J Hematol Oncol"},{"issue":"S1","key":"4258_CR3","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1016\/j.clml.2018.07.149","volume":"18","author":"S Jagannath","year":"2018","unstructured":"Jagannath S, Vogl DT, Dimopoulos M-A, Nooka A, Huff C, Moreau P et al (2018) Phase 2b results of the STORM study: oral selinexor plus low dose dexamethasone (Sd) in patients with penta-refractory myeloma (penta-MM). Clin Lymphoma Myeloma Leuk 18(S1):S249\u2013S250","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"4258_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA et al (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381(8):727\u2013738","journal-title":"N Engl J Med"},{"issue":"7","key":"4258_CR5","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP et al (2020) Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 7(7):e511\u2013e522","journal-title":"Lancet Haematol"},{"issue":"24","key":"4258_CR6","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","volume":"129","author":"R Garzon","year":"2017","unstructured":"Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M et al (2017) A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood 129(24):3165\u20133174","journal-title":"Blood"},{"key":"4258_CR7","doi-asserted-by":"crossref","unstructured":"Bader JC, Abdul Razak AR, Shacham S, Xu H (2021) Pharmacokinetics of selinexor: the first-in-class selective inhibitor of nuclear export. Clin Pharmacok J","DOI":"10.1007\/s40262-021-01016-y"},{"issue":"2","key":"4258_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand M, Karlsson M (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11(2):371\u2013380","journal-title":"AAPS J"},{"issue":"9","key":"4258_CR9","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/A:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO (1998) Automated covariate model building within NONMEM. Pharm Res 15(9):1463\u20131468","journal-title":"Pharm Res"},{"issue":"2","key":"4258_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151","journal-title":"AAPS J"},{"key":"4258_CR11","unstructured":"R Core Team (2016) R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. https:\/\/www.R-project.org\/"},{"issue":"3","key":"4258_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40262-016-0436-x","volume":"56","author":"EA Calvier","year":"2017","unstructured":"Calvier EA, Krekels EH, V\u00e4litalo PA, Rostami-Hodjegan A, Tibboel D, Danhof M et al (2017) Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet 56(3):273\u2013285","journal-title":"Clin Pharmacokinet"},{"issue":"66","key":"4258_CR13","doi-asserted-by":"publisher","first-page":"110503","DOI":"10.18632\/oncotarget.22801","volume":"8","author":"ML Crochiere","year":"2017","unstructured":"Crochiere ML, Hannus S, Hansen K, Becker F, Baloglu E, Klebanov B et al (2017) XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose. Oncotarget 8(66):110503\u2013110516","journal-title":"Oncotarget"},{"issue":"2","key":"4258_CR14","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.18632\/oncotarget.6495","volume":"7","author":"ML Crochiere","year":"2016","unstructured":"Crochiere ML, Baloglu E, Klebanov B, Donovan S, Del Alamo D, Lee M et al (2016) A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds. Oncotarget 7(2):1863\u20131877","journal-title":"Oncotarget"},{"issue":"14","key":"4258_CR15","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston DR, Davis M (2017) Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin Cancer Res 23(14):3489\u20133498","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04258-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T13:03:39Z","timestamp":1621947819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04258-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4258"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04258-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"16 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H. Xu, J.C. Bader, S. Tang, J. Shah, and S. Shacham are employees for Karyopharm Therapeutics. H. Li and R. Wada are employees of Certara and were paid consultants for Karyopharm Therapeutics for the analyses described herein.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}